5:33 PM
 | 
Jul 22, 2010
 |  BC Extra  |  Financial News

Elan reports earnings

Elan Corp. plc (NYSE:ELN) posted a wider 2Q10 net loss due to an expected $203.5 million charge to settle an investigation by the U.S. Department of Justice of Elan's marketing practices for epilepsy drug Zonegran zonisamide. However, the company said...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >